Other equities research analysts also recently issued research reports about the company. ValuEngine raised Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, July 24th. Roth Capital reiterated a “buy” rating on shares of Catalyst Pharmaceuticals in a report on Tuesday, August 11th. Piper Sandler reduced their target price on Catalyst Pharmaceuticals from $7.00 to $6.00 in a report on Tuesday, August 11th. Finally, Oppenheimer reiterated a “buy” rating and issued a $8.00 target price on shares of Catalyst Pharmaceuticals in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $8.67.
Shares of NASDAQ:CPRX opened at $3.42 on Tuesday. The company has a market cap of $353.84 million, a P/E ratio of 8.77 and a beta of 1.54. Catalyst Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $6.75. The business has a fifty day simple moving average of $3.59 and a 200-day simple moving average of $4.16.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported $0.09 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.01. The business had revenue of $29.61 million during the quarter, compared to the consensus estimate of $28.97 million. Catalyst Pharmaceuticals had a return on equity of 44.37% and a net margin of 34.87%. Research analysts forecast that Catalyst Pharmaceuticals will post 0.4 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Schroder Investment Management Group increased its position in shares of Catalyst Pharmaceuticals by 275.6% during the first quarter. Schroder Investment Management Group now owns 1,328,566 shares of the biopharmaceutical company’s stock worth $5,208,000 after acquiring an additional 974,809 shares during the last quarter. Man Group plc increased its position in shares of Catalyst Pharmaceuticals by 869.3% during the second quarter. Man Group plc now owns 1,049,735 shares of the biopharmaceutical company’s stock worth $4,850,000 after acquiring an additional 941,435 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Catalyst Pharmaceuticals by 148.1% during the second quarter. Two Sigma Advisers LP now owns 1,094,592 shares of the biopharmaceutical company’s stock worth $5,057,000 after acquiring an additional 653,400 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Catalyst Pharmaceuticals by 38.1% during the second quarter. Prudential Financial Inc. now owns 1,421,749 shares of the biopharmaceutical company’s stock worth $6,568,000 after acquiring an additional 392,281 shares during the last quarter. Finally, Sontag Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth about $1,300,000. 62.56% of the stock is currently owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Further Reading: Systematic Risk and Investors
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.